C5 and anemia (phenotype): The US Food and Drug Administration (FDA) approved pegcetacoplan in 2021 for the treatment of adults with PNH [22], shortly followed by the European Medicines Agency (EMA)’s approval of it in 2021 for adults with PNH who had anemia after at least 3 months of C5 inhibitor therapy.